[
    [
        {
            "time": "2018-01-03",
            "original_text": "Novo Nordisk Makes $3.1 Billion Takeover Offer For Ablynx",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Takeover Offer",
                    "Ablynx",
                    "$3.1 Billion"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Novo Nordisk Makes $3.1 Billion Takeover Offer For Ablynx",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "CBMG Up 90% In 5 Days, ALDR Delivers On Promise, ABLX Being Pursued By NVO",
            "features": {
                "keywords": [
                    "CBMG",
                    "90%",
                    "ALDR",
                    "ABLX",
                    "NVO"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "CBMG Up 90% In 5 Days, ALDR Delivers On Promise, ABLX Being Pursued By NVO",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "Ablynx Soars After Rejects Novo Nordisk's $3.1 Billion Biotech Bid",
            "features": {
                "keywords": [
                    "Ablynx",
                    "Soars",
                    "Rejects",
                    "Novo Nordisk",
                    "$3.1 Billion"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Ablynx Soars After Rejects Novo Nordisk's $3.1 Billion Biotech Bid",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "Novo Nordisk Revises Up Offer For Ablynx To $3.1 Billion",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Revises Up",
                    "Offer",
                    "Ablynx",
                    "$3.1 Billion"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novo Nordisk Revises Up Offer For Ablynx To $3.1 Billion",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "Ozempic Could Boost Novo Nordisk’s Revenue Growth in 2018",
            "features": {
                "keywords": [
                    "Ozempic",
                    "Boost",
                    "Novo Nordisk",
                    "Revenue Growth",
                    "2018"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Ozempic Could Boost Novo Nordisk’s Revenue Growth in 2018",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "ABLYNX STRONGLY BELIEVES UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK FUNDAMENTALLY UNDERVALUES THE COMPANY AND ITS FUTURE PROSPECTS",
            "features": {
                "keywords": [
                    "ABLYNX",
                    "Believes",
                    "Unsolicited Proposal",
                    "NOVO NORDISK",
                    "Undervalues",
                    "Future Prospects"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "ABLYNX STRONGLY BELIEVES UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK FUNDAMENTALLY UNDERVALUES THE COMPANY AND ITS FUTURE PROSPECTS",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-09",
            "original_text": "Novo Nordisk Bids $3.1 Billion For Belgian Biotech Group Ablynx",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Bids",
                    "$3.1 Billion",
                    "Belgian",
                    "Biotech",
                    "Ablynx"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novo Nordisk Bids $3.1 Billion For Belgian Biotech Group Ablynx",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-10",
            "original_text": "Novo Goes Public With $3.1 Billion Bid To Pressure Ablynx",
            "features": {
                "keywords": [
                    "Novo",
                    "Public",
                    "$3.1 Billion",
                    "Bid",
                    "Pressure",
                    "Ablynx"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novo Goes Public With $3.1 Billion Bid To Pressure Ablynx",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]